Sage gains after striking license agreement with Biogen
Check out this morning's top movers from around Wall Street, compiled by The Fly.
Sage Therapeutics (SAGE) up 7% after announcing a global collaboration and license agreement with Biogen (BIIB) to jointly develop and commercialize zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders
Rhythm Pharmaceuticals (RYTM) up 13% after announcing the FDA has approved Imcivree for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1 or leptin receptor deficiency confirmed by genetic testing
Sorrento Therapeutics (SRNE) up 17% after the company announced subsidiary SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop a rapid countermeasure to COVID-19
Riot Blockchain (RIOT) down 13% as bitcoin continues to come off recent highs
Keywords: Wall Street, Top Stories, Stocks, Pre-market